All In Biotech

Drug Trial Radar · NCT07452692

A Study to Assess the Skin Irritation and Sensitization of Selegiline TDS in Healthy Subjects

Assessment of the Irritation and Sensitization Potential of a Selegiline Transdermal Delivery System (6 mg/24 h) as Compared to a Reference Product (EMSAM® 6 mg/24 h)

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 232 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

232

Actual

Start

Aug 23, 2026

Primary completion

Sep 26, 2026

Study completion Sep 26, 2026

Sponsor

Lead sponsor
Corium Innovations, Inc.Industry
Sponsor type
Industry
First posted
Mar 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
Single (outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The two products used in this study are transdermal patches that contain selegiline. The test drug is the Selegiline Transdermal Delivery System (TDS). The comparator drug is the EMSAM® TDS. The purpose of this research study is to compare how the skin tolerates the test TDS and the comparator TDS. The study will evaluate and compare skin irritation and possible allergic-type skin reactions (sensitization) caused by the two products. The comparison will be based on how the skin responds to repeated applications of each TDS. This includes the assessment of skin irritation during the Induction Period and the evaluation of possible allergic or sensitization reactions after the Challenge Period. In addition, the adhesion of each patch (how well the patch sticks to the skin over time) will be regularly checked, as this is important for both product performance and skin safety.

Conditions

  • Major Depressive Disorder (MDD)

Interventions

  • Selegiline Transdermal Delivery SystemDrug

    1/2 Selegiline TDS patch 6 mg/24 hours and 1/2 EMSAM® patch 6 mg/24 hours will be administered simultaneously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of irritationTime frame: From enrollment through the induction, challenge and potential rechallenge phases, up to 15 weeks.
  2. Assessment of sensitizationTime frame: From enrollment through induction, challenge and potential re-challenge phase, up to 15 weeks.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • MHAT Skin Systems EOOD

    Elin Pelin, Bulgaria

  • Diagnostic & Consultative Center "Ascendent" Ltd.

    Sofia, Bulgaria

  • Medical Center Neovitro

    Sofia, Bulgaria

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.